SEARCH

SEARCH BY CITATION

References

  • 1
    Murphy WF, Foley M, Doherty C, Tierney G, Kinsella A, Salami A, Cadden E, Coakley P: Screening platelet concentrates for bacterial contamination: Low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008; 95:1319
  • 2
    Alter HJ: Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008; 22:97102
  • 3
    Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY: Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49(Suppl. 2):1S49S
  • 4
    FDA Blood Products Advisory Committee transcript, November 16-17, 2009. http://www.fda.gov/downloads/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM193385.pdf. Last accessed 30 December 2009.
  • 5
    Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F: Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47:23382347
  • 6
    Prowse C: Properties of pathogen-inactivated plasma components. Transfus Med Rev 2009; 23:124133
  • 7
    Pelletier JP, Transue S, Snyder EL: Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006; 19:205242
  • 8
    Horowitz B, Bonomo R, Prince AM, Chin SN, Brokman B, Shulman RW. Solvent/detergent-treated plasma. A virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79:826833
  • 9
    Hellstern P: Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma? Transfus Apher Sci 2008; 39:6974
  • 10
    Brown KE, Young NS, Alving BM, Barbosa LH: Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 2001; 41:130135
  • 11
    Neisser-Svae A, Bailey A, Gregori L, Heger A, Jordan S, Behizad M, Reichl H, Römisch J, Svae TE: Prion removal effect of a specific affinity ligand introduced in the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG®. Vox Sang 2009; 97:226233
  • 12
    Segal JB, Dzik WH: Transfusion Medicine/Hemostasis Clinical Trials Network: paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45:14131425
  • 13
    Hellstern P: Solvent/detergent-treated plasma: composition, efficacy and safety. Curr Opin Hematol 2004; 11:346350
  • 14
    De Jonge J, Groenland TH, Metselaar HJ, IJzermans JN, Van Vliet HH, Visser L, Tilanus HW: Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 2002; 94:11271131
  • 15
    Magner JJ, Crowley KJ, Boylan JF: Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth 2007; 21:410413
  • 16
    Williamson LM, Cardigan R, Prowse PV: Methylene-blue-treated fresh-frozen plasma: what is its contribution to blood safety. Transfusion 2003; 43:13221329
  • 17
    Lachert E, Kubis J, Antoniewicz-Papis J, Goller A, Letowska M, Kulla G: Comparative study of treated and untreated fresh frozen plasma as source of fibrinogen concentrates obtained from methylene blue treated plasma from MacoPharma Maco-Tronic system. Vox Sang 2006; 91(Suppl. 3):182
  • 18
    Lorenz M, Muller M, Jablonka B, Vigh T, Kirchmaier CM: High doses of methylene blue/light treatment crosslink the A-alpha subunit of fibrinogen: influence of this photooxidization on fibrinogen binding to platelets. Haemostasis 1998; 28:1724
  • 19
    Heger A, Pock K, Janisch S, Svae T-E, Römisch J: Thrombin generation capacity is impaired in MB treated plasma units compared to FFP, a pharmaceutically licensed S/D treated plasma product, and a universally applicable S/D plasma under development. Vox Sang 2007; 93(Suppl. 1):210
  • 20
    Cardigan R, Philpot K, Cookson P, Luddington R: Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate. Transfusion 2009; 49:696703
  • 21
    Hernandez JM, Castella D, Claparols M, Sauleda A, Masuet L: Clinical use of fresh frozen plasma virus inactivated with methylene blue. Transfusion 1999; 39(suppl 1):25S
  • 22
    Wieding JU, Neumeyer H: Initial experience with methylene blue virus inactivated fresh frozen plasma: results of a clinical and in vitro study. Infusionsther Transfusionsmed 1992; 19:8490
  • 23
    Atance R, Pereira A, Ramírez B: Transfusion methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001; 41:15481552
  • 24
    Del Rio-Garma J, Alvarez-Larran A, Martinez C, De La Rubia J, Zamora C, Muncunill J, Corral M, Garcia-Noblejas A, Mateo J, Muñoz J, Gomez-Arteta E, Pujol M, Jimenez JM, Rodriguez-Vicente P, Contrearas E, Arbona C, Pereira A: Methylene blue photoinactivated plasma (MBPIP) vs. Fresh Frozen Plasma (FFP) in the treatment of idiopathic thrombotic thrombocytopenic purpura (TTP): A multicentre prospective-cohort study. Vox Sang 2007; 93(Suppl. 1):41
  • 25
    Larrea L, Calabuig M, Roldán V, Rivera J, Tsai H-M, Vicente V, Roig R: The influence of riboflavin photochemistry on plasma coagulation factors. Transfus Apher Sci 2009; 41:199204
  • 26
    Bihm DJ, Ettinger A, Buytaert-Hoefeb KA, Hendrix BK, Maldonado-Codina G, Rock G, Giclas PC, Goodrich RP: Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at −30ºC. Vox Sang 2010; 98:108115
  • 27
    Hambleton J, Wages D, Radu-Radulescu L, Adams M, MacKenzie M, Shafer S, Lee M, Smyers J, Wiesehahn G, Corash L: Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002; 42:13021307
  • 28
    Irsch J, Pinkowski L, Corash L, Lin L: INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function – an in vitro analysis. Vox Sang 2009; 98:4755
  • 29
    De Alarcon P, Benjamin R, Dugdale M et al. : Fresh frozen plasma prepared with amotosalen (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45:13621372
  • 30
    Cazenave JP, Waller C, Kientz D, Mendel I, Lin L, Jacquet M, Propst M, Liu W, Corash L, Sundin D, Defoin L, Messe N, Osselaer JC: An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion (in press)
  • 31
    Mintz PD, Bass NM, Petz LD, Steadman R, Strieff M, McCullough J, Burks S, Wages D, Van Doren S, Corash L: Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107:37533760
  • 32
    Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Roualt C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG: A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet light A compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46:16931704
  • 33
    Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J, Burks S, Wages D, Van Doren S, Corash L: Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 10:37533760
  • 34
    Mohr H, Graveman U, Müller TH: Inactivation of pathogens in single units of therapeutic fresh plasma by irradiation with ultraviolet light. Transfusion 2009; 49:21442151
  • 35
    Pyke AD, Blajchman MA: The pathogen inactivation of platelets: studies of the possible mechanisms of the platelet dysfunction seen following photochemical treatment. Blood 2006; 108(Suppl):175a
  • 36
    Gelderman-Fuhrman MP, Lewis JL, Tassis EK, Vostal AC, Vostal JG: Comparison of UVA and UVB induced lesions in human platelets evaluated in an animal model. Blood 2007; 110:848A
  • 37
    Picker SM, Schneider V, Oustianskaia L, Gathof BS: Cell viability during platelet storage in correlation to cellular after different pathogen reduction technologies. Transfusion 2009; 49:23112318
  • 38
    Picker SM, Oustianskaia L, Schneider V, Gathof BS: Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2008; 97:2633
  • 39
    Picker SM, Schneider V, Gathof BS: Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009; 49:12241232
  • 40
    Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, Corash L, Lin L: Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91:21802188
  • 41
    Fast LD, DiLeone G, Li J, Goodrich R: Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46:642648
  • 42
    Asano H, Lee C-Y, Fox-Talbot K, Koh CM, Erdinc MM, Marschner S, Keil S, Goodrich RP, Baldwin WM III: Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84:11741182
  • 43
    Fast LD, DiLeone G, Cardarelli G, Li J, Goodrich R: Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2−/−γc−/− double knockout mice. Transfusion 2006; 46:15531560
  • 44
    Luban NL: Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Semin Hematol 2001;38(4 Suppl 11):3445.
  • 45
    Van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, De Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101:24262433
  • 46
    McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104:15341541
  • 47
    Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG, SPRINT Study Group: Clinical safety of platelets photochemical treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; 45:18641875
  • 48
    Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padrón F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L: An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94:315323
  • 49
    Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, Van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L: Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009; 49:14121422
  • 50
    Kerkhoffs JH, Novotny VM, Boekhorst PAT, Schipperus MR, Zwaginga JJ, Van Pampus L, Van Putten WL, Huijgens PC, Brand A, Van Rhenen DJ: Clinical effectiveness and safety of pooled, random donor platelet concentrates, leucoreduced and stored up to seven days in either plasma or additive solution with and without pathogen reduction in hemato-oncological patients. Transfusion 2009; 49:2A3A (abstract).
  • 51
    Lozano M, Knutson F, Tardivel R, Cid J, Maymo R-M, Lof H, Rodie H, Pelly J, Docherty A, Sherman C, Lin L, Propst M, Corash L, Prowse C: A multi-center study of therapeutic efficacy and safety of platelet components prepared with pathogen inactivation (InterceptTM) stored for 6 or 7 days prior to transfusion. Miguel Lozano, personal communication, March, 2010.
  • 52
    The Mirasol Clinical Evaluation Study Group: A randomized controlled clinical trial evaluating the performance and safety of platelet treated with Mirasol® pathogen reduction technology. Ray Goodrich, personal communication, March, 2010
  • 53
    Terpstra FG, Van ‘tWout AB, Schuitemaker H, Van Engelenburg FAC, Dekkers DWC, Verhaar R, De Korte D, Verhoeven AJ: Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates. Transfusion 2008; 48:304313
  • 54
    Mohr H, Gravemann U, Bayer A, Müller TH: Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009; 49:19561963
  • 55
    Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, Müller TH, Völker U: A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49:26122624
  • 56
    Mohan KVK, Rao AA, Atreya CD: Evaluation of antimicrobial peptides as novel bactericidal agents for room temperature–stored platelets. Transfusion 2010; 50:166173
  • 57
    Tanaka S, Hayashi T, Tateyama H, Matsumura K, Hyon S-H, Hirayama F: Application of the bactericidal activity of ε-poly-L-lysine to the storage of human platelet concentrates. Transfusion 2010; 50: 932940
  • 58
  • 59
    Goodrich RP, Murthy KK, Doane SK, Fitzpatrick CH, Morrow LS, Arndt PA et al. : Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons. Transfusion 2009; 49:6474
  • 60
    Goodrich RP, Doane S, Reddy HL: Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals. 2010; 38:2030
  • 61
    Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Lessinger C, Granger S: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600613
  • 62
    Wandt H, Schaefer-Eckart K, Pilz B, Thalheimer M, Ho AD, Schaich M, Kaufman M, Aulitzky WE, Haenel M, Herbst R, Doelken G, Klenner AF, Freund M, Junghanss C, Ehninger G: Experience with a therapeutic platelet transfusion strategy in acute myeloid leukemia: preliminary results of a randomized multicenter study after enrolment of 175 patients. (abstract) Blood 2009;114:14